News Briefing channel feed

News brief­ing: Seer heads to Nas­daq with $150M IPO; IN8bio post­pones pub­lic de­but amid record year on Wall Street

5 years ago

News brief­ing: Small merg­er to ad­vance an­ti-ag­ing pro­gram; Sanger In­sti­tute spin­out nabs $50M from Se­ries C

5 years ago

Gates Foun­da­tion backs a new sick­le cell CRISPR ap­proach; Sid­dhartha Mukher­jee's Vor adds a new CAR-T

5 years ago

News brief­ing: Lo­cus Bio­sciences bags up to $12.1M for CRISPR an­tibac­te­r­i­al; Old Ver­tex drug heads to PhI­II for de­men­tia

5 years ago

News brief­ing: In­tel­lia hits clin­ic with CRISPR ther­a­py; Vi­for con­tin­ues to spend, pay­ing up to $340M for DGF pro­gram

5 years ago

News brief­ing: Chi­nese can­cer play­er gets $124M+ Se­ries C; IN8bio sets terms for $86M IPO

5 years ago

News brief­ing: Cosen­tyx shows ear­ly pos­i­tive signs in pso­ri­at­ic arthri­tis; Pfiz­er's PhI­Ib for car­dio drug trig­gers $75M mile­stone

5 years ago

News brief­ing: Gilead sub­mits fil­go­tinib to Eu­ro­pean reg­u­la­tors for UC; GW Phar­ma­ceu­ti­cals launch­es PhI­II tri­al for MS can­di­date made with cannabis ex­tracts

5 years ago

News brief­ing: FDA lifts a hold on Po­sei­da study; Deci­bel adopts 2-AAV ap­proach to hear­ing loss; As­traZeneca part­ners on com­bos, again

5 years ago

News brief­ing: Ax­o­vant faces months of de­lay on lead Parkin­son's gene ther­a­py; Chi­nese CAR-T biotech nabs $100M

5 years ago

News brief­ing: Spring­Works, Jazz ex­change $35M and PTSD drug; Dr. Red­dy's says cy­ber­at­tack was ran­somware

5 years ago

News brief­ing: No­var­tis' Zol­gens­ma hits block­buster sta­tus, trig­ger­ing $80M mile­stone; Caris rais­es $310M for ge­nom­ic pro­fil­ing ex­pan­sion

5 years ago

News brief­ing: As­traZeneca fol­lows Am­gen down KRAS/SHP2 com­bo path; Val­lon Phar­ma­ceu­ti­cals files for $17 mil­lion IPO 

5 years ago

News brief­ing: Gilead com­pletes $21B buy­out of Im­munomedics; In­nate re­ceives $50M mile­stone pay­ment from As­traZeneca

5 years ago

News brief­ing: UK biotech 4D phar­ma heads for Nas­daq via SPAC; Dr. Red­dy's shuts down man­u­fac­tur­ing af­ter cy­ber­at­tack

5 years ago

Pur­due Phar­ma signs guilty plea, preps $8B+ set­tle­ment on Oxy con­tro­ver­sy — re­port; Flag­ship brings in a comms chief

5 years ago
R&D

News brief­ing: Mer­ck preps FDA pitch af­ter adding more da­ta on V114; Bris­tol My­ers, Ex­elix­is get quick re­view for can­cer com­bo

5 years ago

News brief­ing: Ab­b­Vie and Roche's Ven­clex­ta scores an­oth­er FDA OK; Im­muno­Gen nabs Chi­na deal with $40M cash

5 years ago

News brief­ing: A sweep of CHMP OKs for Al­ny­lam, Kite, No­var­tis and oth­ers; Sanofi's big can­cer play gets OK from UK watch­dog

5 years ago

News brief­ing: Ot­su­ka’s $886M can­cer drug is now a 3-time los­er in PhI­II; Keytru­da ap­proved for clas­si­cal Hodgkin lym­phoma

5 years ago

News brief­ing: No­vo eyes the next ki­nas­es in a Finnish start­up; Boehringer In­gel­heim brings a bis­pe­cif­ic to the clin­ic

5 years ago

News brief­ing: Re­gen­eron/Sanofi post pos­i­tive PhI­II Dupix­ent da­ta in pe­di­atric asth­ma; Vineti scores $33M Se­ries C ex­ten­sion

5 years ago

News brief­ing: Gilead re­veals more fil­go­tinib da­ta; Seagen and Astel­las re­port new co­hort for Pad­cev

5 years ago

News brief­ing: Pfiz­er on track to ear­ly '22 piv­otal read­out on he­mo­phil­ia A; Co­di­ak scales back IPO ex­pec­ta­tions

5 years ago
First page Previous page 35363738394041 Next page Last page
A service from the Financial Times